GCM
BEAM icon

Graham Capital Management’s Beam Therapeutics BEAM Stock Holding History

Graham Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,811
Closed -$384K – 1233
2025
Q3 		$384K Sell
15,811
-5,464
-26% -$109K 0.01% 735
2025
Q2 		$362K Buy
+21,275
New +$370K 0.01% 932
2025
Q1 		– Sell
-12,364
Closed -$307K – 1296
2024
Q4 		$307K Buy
12,364
+1,954
+19% +$49.9K ﹤0.01% 922
2024
Q3 		$255K Sell
10,410
-13,989
-57% -$361K ﹤0.01% 842
2024
Q2 		$572K Buy
+24,399
New +$599K 0.01% 544
2022
Q3 		– Sell
-135,588
Closed -$5.25M – 1067
2022
Q2 		$5.25M Buy
+135,588
New +$5.39M 0.21% 55

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Graham Capital Management's BEAM Position: Q4 2025 in Review

Graham Capital Management sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 15,811 shares — an estimated $384K sold.

Graham Capital Management first reported a position in BEAM in Q2 2022 and held it in 6 quarters. The position peaked at $5.25M in Q2 2022. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Graham Capital Management reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 15,811 Beam Therapeutics shares in Q4 2025, an estimated $384K.
  • Graham Capital Management first reported a position in Beam Therapeutics in Q2 2022 and held it in 6 quarters.
  • Graham Capital Management's Beam Therapeutics position peaked at $5.25M in Q2 2022.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.